The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | DREAMM-9: extended belantamab dosing and vision-related outcomes in myeloma
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, The University of Melbourne, Melbourne, Australia, discusses patient-reported outcomes from the Phase I DREAMM-9 trial (NCT04091126), evaluating extended belantamab mafodotin dosing intervals in combination with bortezomib, lenalidomide and dexamethasone (BVRd) in transplant-ineligible newly diagnosed multiple myeloma. Prof. Quach highlights how extended dosing intervals reduced severe ocular adverse events and preserved vision-related functioning while maintaining efficacy, supporting the optimization of belantamab dosing during induction and maintenance. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
